Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.55 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.55 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.55 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.55 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.55 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.55 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.55 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22127721 | 0.98 | ABL1 (0.56) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL1180343 | 0.85 | ABL1 (0.69) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL29489425 | 0.85 | CYP3A4 (0.73) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL196765 | 0.85 | CYP3A4 (0.73) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL458391 | 0.83 | CYP1A1 (0.64) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL29740761 | 0.83 | CYP1A1 (0.64) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| Ammonia Solution, Strong SCHEMBL27960505 | 0.83 | CYP3A4 (0.70) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| Hydrogen Sulfide SCHEMBL28640169 | 0.83 | CYP3A4 (0.70) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL29628977 | 0.83 | CYP3A4 (0.77) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL2753072 | 0.81 | ABL1 (0.57) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111533697-B | 4-aminopyridazinone compound and preparation method thereof | 成都大学 | 2023-03-31 | — | — | CN | claimed |
| CN-115385956-A | Biaryl diphosphine ligands and transition metal complexes thereof | 东莞市均成高新材料有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-110357989-A | Tertiary amine photosensitizer, preparation method, comprising its photosensitive polymer combination and photosensitive polymer combination application | 常州强力电子新材料股份有限公司 | 2019-10-22 | — | — | CN | claimed |
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) | 2018-09-18 | — | — | US | claimed |
| WO-2017078927-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | claimed |
| EP-3116851-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | Salk Institute for Biological Studies (US) | 2017-01-18 | — | — | EP | claimed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | claimed |
| WO-2015138969-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-09-17 | — | — | WO | claimed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | claimed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | claimed |
| WO-2003051879-A1 | KNOWN AND NOVEL 4,5-DIHYDRO-IMIDAZO[4,5,1-IJ]QUINOLIN-6-ONES USEFUL AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| US-20030109517-A1 | Azacycloalkanone serine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-12 | — | — | US | claimed |
| US-6469029-B1 | INHIBITORS OF THROMBIN PRODUCTION VIA FACTOR XA INHIBITION; COUPLED TO MEDICAL DEVICES, SUCH AS STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-22 | — | — | US | claimed |
| CN-1373755-A | Azacycloalkanone serine protease inhibitors | DIMENSIONAL PHARM INC (US) | 2002-10-09 | — | — | CN | claimed |
| EP-1212300-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001019795-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-6090841-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | claimed |
| EP-0589018-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1994-03-30 | — | — | EP | claimed |
| WO-1993020807-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | claimed |
| US-5223640-A | Regioselectively silylcarbonylating arylacetylene, oxidizing, desilylating, hydrogenating | HOECHST CELANESE CORPORATION (US) | 1993-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | LIPA, MGLL, PNLIP | CYP3A4 1609/4885CYP1A1 1751/4885CYP1A2 878/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | CYP3A4 1198/4885CYP1A1 299/4885CYP1A2 159/4885 |
| US-20030109517-A1 | Azacycloalkanone serine protease inhibitors | CTRL, SERPINE1, SERPINB1 | CYP3A4 1924/4885CYP1A1 753/4885CYP1A2 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.